Wedbush Has Optimistic Outlook of BCRX Q4 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at Wedbush boosted their Q4 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research note issued on Monday, November 3rd. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings of $0.06 per share for the quarter, up from their previous estimate of $0.05. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ FY2029 earnings at $1.94 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. BioCryst Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.07) earnings per share. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS.

A number of other research firms have also recently commented on BCRX. Citizens Jmp lowered their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Needham & Company LLC decreased their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Cantor Fitzgerald increased their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $7.09 on Thursday. The firm’s fifty day moving average is $7.45 and its two-hundred day moving average is $8.66. The firm has a market cap of $1.49 billion, a PE ratio of -39.39 and a beta of 1.09. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31.

Insider Transactions at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of BioCryst Pharmaceuticals by 6.1% in the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after purchasing an additional 1,246,633 shares in the last quarter. State Street Corp increased its stake in BioCryst Pharmaceuticals by 8.9% in the 2nd quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock valued at $76,208,000 after buying an additional 691,988 shares during the last quarter. Alkeon Capital Management LLC increased its stake in BioCryst Pharmaceuticals by 1.7% in the 1st quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock valued at $54,105,000 after buying an additional 120,199 shares during the last quarter. Geode Capital Management LLC lifted its position in BioCryst Pharmaceuticals by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock worth $45,296,000 after buying an additional 93,973 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of BioCryst Pharmaceuticals by 2,103.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock worth $38,336,000 after buying an additional 4,084,403 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.